Indication
MSI-H Colorectal Cancer
10 clinical trials
10 products
7 drugs
Clinical trial
A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid MalignanciesStatus: Terminated, Estimated PCD: 2023-11-01
Product
PembrolizumabProduct
ATRC-101Clinical trial
A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2023-04-06
Product
CDX-527Clinical trial
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2024-04-22
Product
PD-1 AntibodyDrug
mFOLFOX6Drug
UTD1Clinical trial
Randomized Trial of Regorafenib in Combination With Pembrolizumab or Pembrolizumab Monotherapy With an Efficacy Lead-in of Regorafenib and Pembrolizumab for Patients With MSI-H Colorectal CancerStatus: Not yet recruiting, Estimated PCD: 2026-04-01
Drug
RegorafenibClinical trial
Analysis of the Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer: A GERCOR Open-label, Randomized, Non-comparative, Two-stage Phase II Trial (NIPISAFE).Status: Recruiting, Estimated PCD: 2027-04-01
Product
Nivolumab + IpilimumabClinical trial
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified CutoffStatus: Recruiting, Estimated PCD: 2025-09-30
Drug
SpartalizumabProduct
TislelizumabClinical trial
A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid TumoursStatus: Recruiting, Estimated PCD: 2024-08-01
Product
FosifloxuridineDrug
DocetaxelClinical trial
Immunological Variables Associated to ICI Toxicity in Cancer PatientsStatus: Recruiting, Estimated PCD: 2024-06-01
Product
Checkpoint Blockade ImmuneClinical trial
A Phase II Study of Niraparib in Combination With EGFR Inhibitor Panitumumab in Patients With Advanced Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2024-10-31
Drug
AtezolizumabProduct
PanitumumabClinical trial
Multicenter, Single-arm, Open-label Phase II Clinical Study of Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal CancerStatus: Not yet recruiting, Estimated PCD: 2024-12-31